A story about Incyte Genetics in the Aug. 18, 1998, issue of BioWorld Today should have said the $200 million Incyte Genetics will spend in its first two years includes the $38 million acquisition of Hexagen Inc., $20 million to $30 million in cash from Incyte Pharmaceuticals Inc., investments from strategic partners and the equity markets, plus subscription revenues and fees from pharmacogenetics products.